Article

Congress awaits approval of eye trauma measure for injured active-duty service members

Washington, DC-Congress is awaiting presidential approval of legislation designed to improve the ability of the Department of Defense (DoD) and the Veterans Health Administration to treat members of the military who have suffered serious eye injuries while on active duty.

Washington, DC-Congress is awaiting presidential approval of legislation designed to improve the ability of the Department of Defense (DoD) and the Veterans Health Administration to treat members of the military who have suffered serious eye injuries while on active duty.

The legislation, which Congress passed as part of the National Defense Authorization Act, would establish a Center of Excellence within the DoD to improve the tracking, diagnosis, treatment, and follow-up for service members who have incurred eye injuries. It also would create a formal registry that would house electronic records and enable the DoD and Department of Veterans Affairs to share patient information. The measure passed by Congress does not provide for funding for the center or registry, however.

The legislation was presented to President George W. Bush Dec. 19, but Dec. 28 he announced that he was withholding approval.

The American Academy of Ophthalmology has joined the Blinded Veterans Association and other veterans’ service organizations in support of the legislation.

Related Videos
(Image credit: Ophthalmology Times) AGS 2025: A look at Gemini and the MIGS revolution with Mona Kaleem, MD
(Image credit: Ophthalmology Times) AGS 2025: Development and evaluation of an AI model to set target IOP with Jithin Yohannan, MD, MPH
(Image credit: Ophthalmology Times) NeuroOp Guru: The role of muscle biopsy in heteroplasmy detection
(Image credit: Ophthalmology Times) AGS 2025: Achieving success as an academic ophthalmologist with Thomas V. Johnson III, MD, PhD
(Image credit: Ophthalmology Times) AGS 2025: Constance Okeke, MD, highlights 1-year Streamline canaloplasty outcomes
© 2025 MJH Life Sciences

All rights reserved.